

CERTIFICATE OF ANALYSIS

Tesamorelin - 5 mg


Synthetic 44-residue GHRH analogue - N-terminal trans-3-hexenoyl group - lyophilised

Material	Tesamorelin	Client	novumpeptides.com	Received	2026-09-15 at 2-8 C
Batch / lot	PEP-44-8NS	Label claim	5 mg	Analysed	2026-09-16 to 2026-09-17

TEST RESULTS

ATTRIBUTE	RESULT	SPECIFICATION	METHOD	VERDICT
Identity	Conforms	Matches reference	MA-MS-014 / LC-HRMS	Conforms
Purity (area %)	99.38%	$\geq 99.00\%$	MA-UHPLC-031 / UV 214	Pass
Largest single impurity	0.19%	$\leq 0.50\%$	MA-UHPLC-031 / UV 214	Pass
Total related substances	0.62%	$\leq 1.00\%$	MA-UHPLC-031 / UV 214	Pass
Tesamorelin per vial	4.98 mg	4.50-5.50 mg	MA-ASSAY-011 / UHPLC-UV	Pass
Water content	4.46%	$\leq 8.00\%$	MA-KF-004 / Karl Fischer	Pass
Residual acetonitrile	176 ppm	≤ 410 ppm	MA-GC-006 / HS-GC-FID	Pass
Residual TFA	0.20%	$\leq 1.00\%$	MA-IC-003 / ion chromatography	Pass

RP-UHPLC processed trace, UV detection



Record 5W3F8NS-PEP-01; duplicate independent preparations. System suitability met retention-time and resolution criteria; blank response was below threshold.

Related species profile

Related peak A	0.19%
Related peak B	0.14%
Related peak C	0.10%
Related peak D	0.08%
Related peak E	0.06%
Related peak F	0.05%

Related species reported by integrated UV peak area. Structural assignments are not made. Reporting threshold: 0.03% area.

Conclusion

Identity and quality attributes met the stated criteria. Mean Tesamorelin content was 4.98 mg/vial and chromatographic purity was 99.38%.

Identity was established by LC-HRMS against a qualified reference; content and related substances were assessed independently.

Analytical review

Ines Abadi *I. Abadi*

Quality review

Marcus Oyelaran

Prepared: 2026-09-18 *M. Oyelaran*

Decision rule: simple acceptance; reported results are compared directly with the stated project specifications.